Do you want to read an article? Please log in or register.
Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer
Genitourinary Cancer
COMMENTED
Related content
COMMENTED
Genitourinary CancerNuclear Medicine
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
★ 3
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Lancet
Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, Crosby M, Piulats JM, Fléchon A, Wei XX, Mahammedi H, Roubaud G, Študentová H, Nagarajah J, Mellado B, Montesa-Pino Á, Kpamegan E, Ghebremariam S, Kreisl TN, Wilke C, Lehnhoff K, Sartor O, Fizazi K, PSMAfore Investigators
doi: 10.1016/S0140-6736(24)01653-2
Genitourinary Cancer
Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients
Prostate
Tanegashima T, Shiota M, Tsukahara S, Mutaguch J, Goto S, Kobayashi S, Matsumoto T, Eto M
doi: 10.1002/pros.24769
COMMENTED
Genitourinary CancerNuclear Medicine
Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
★ 1
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
J Clin Med
Kınıkoğlu O, Öven BB, Çelik S, Alan Selçuk N, Beydağı G, Akçay K, Kabasakal L
doi: 10.3390/jcm13164585
Genitourinary Cancer
Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis
Prostate Cancer Prostatic Dis
Matsukawa A, Yanagisawa T, Parizi MK, Laukhtina E, Klemm J, Fazekas T, Mori K, Kimura S, Briganti A, Ploussard G, Karakiewicz PI, Miki J, Kimura T, Rajwa P, Shariat SF
doi: 10.1038/s41391-024-00886-0
Genitourinary Cancer
Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
JAMA Netw Open
George DJ, Morgans AK, Constantinovici N, Khan N, Khan J, Chen G, Hlebec V, Shore ND
doi: 10.1001/jamanetworkopen.2024.29783
Genitourinary Cancer
Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis
JAMA Oncol
El-Taji O, Taktak S, Jones C, Brown M, Clarke N, Sachdeva A
doi: 10.1001/jamaoncol.2024.1549
Genitourinary Cancer
Screening for Predictive Factors of Efficacy of Second-Generation Androgen Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Prostate
Ueda T, Hayakawa K, Horiguchi G, Murashita J, Shiraishi T, Fujimoto S, Miyashita M, Saito Y, Gabata Y, Sako S, Takahashi H, Fujihara A, Minami T, Yamamoto Y, Okumi M, Hongo F, Okihara K, Fujita K, Ukimura O
doi: 10.1002/pros.24855
Genitourinary Cancer
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis
J Clin Oncol
Fallah J, Xu J, Weinstock C, Gao X, Heiss BL, Maguire WF, Chang E, Agrawal S, Tang S, Amiri-Kordestani L, Pazdur R, Kluetz PG, Suzman DL
doi: 10.1200/JCO.23.02105
Breast Cancer
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
Clin Cancer Res
Mamounas EP, Bandos H, Rastogi P, Zhang Y, Treuner K, Lucas PC, Geyer CE, Fehrenbacher L, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil S, Paik S, Swain SM, Sgroi DC, Schnabel CA, Wolmark N
doi: 10.1158/1078-0432.CCR-23-1977